{"id":11277,"date":"2025-07-27T02:59:18","date_gmt":"2025-07-27T00:59:18","guid":{"rendered":"https:\/\/valintermed.com\/?p=11277"},"modified":"2025-07-27T02:59:18","modified_gmt":"2025-07-27T00:59:18","slug":"fetalnyy-talidomidnyy-sindrom","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/fetal-talidomidine-syndrome\/","title":{"rendered":"Fetal thalidomide syndrome"},"content":{"rendered":"
<\/div>\n

Fetal thalidomide syndrome (FTS) is a congenital syndrome that develops in a fetus as a result of a pregnant woman's exposure to thalidomide. Thalidomide, originally developed as an antiemetic, has become known for its teratogenic properties, causing a number of serious developmental abnormalities in newborns if the drug is used in the first trimester of pregnancy. The main manifestations of FTS include underdevelopment of the limbs (micromelia), abnormalities of the structure of the ears, eyes, and heart, as well as developmental abnormalities in other organs. These changes are a consequence of the effect of the substance on the processes of cellular migration and differentiation, which significantly complicates not only the physical but also the social development of children born with this syndrome.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n